Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2006

Hulit J, Lee RJ, Li Z, Wang C, Katiyar S, Yang J, et al. p27Kip1 repression of ErbB2-induced mammary tumor growth in transgenic mice involves Skp2 and Wnt/beta-catenin signaling. Cancer Res. 2006;66(17):8529-41.

Signoretti S, Loda M. Defining cell lineages in the prostate epithelium. Cell Cycle. 2006;5(2):138-41.

Keller SA, Hernandez-Hopkins D, Vider J, Ponomarev V, Hyjek E, Schattner EJ, et al. NF-kappaB is essential for the progression of KSHV- and EBV-infected lymphomas in vivo. Blood. 2006;107(8):3295-302.

Kazakov DV, Kutzner H, Palmedo G, Boudova L, Michaelis S, Michal M, et al. Primary cutaneous lymphoproliferative disorders with dual lineage rearrangement. Am J Dermatopathol. 2006;28(5):399-409.

Ogino S, Cantor M, Kawasaki T, Brahmandam M, Kirkner GJ, Weisenberger DJ, et al. CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies. Gut. 2006;55(7):1000-6.

A Crowson N, Magro CM, Mihm MC. Prognosticators of melanoma, the melanoma report, and the sentinel lymph node. Mod Pathol. 2006;19 Suppl 2:S71-87.

Nucera C, Vaccaro M, Moleti M, Priolo C, Tortorella G, Angioni A, et al. antiphospholipid antibodies syndrome associated with hyperhomocysteinemia related to MTHFR Gene C677T and A1298C heterozygous mutations in a young man with idiopathic hypoparathyroidism (DiGeorge syndrome). J Clin Endocrinol Metab. 2006;91(6):2021-6.

Chung KY, Morrone G, Schuringa JJ, Plasilova M, Shieh J-, Zhang Y, et al. Enforced expression of NUP98-HOXA9 in human CD34(+) cells enhances stem cell proliferation. Cancer Res. 2006;66(24):11781-91.

Kim M, Gans JD, Nogueira C, Wang A, Paik J-, Feng B, et al. Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell. 2006;125(7):1269-81.

Piva R, Pellegrino E, Mattioli M, Agnelli L, Lombardi L, Boccalatte F, et al. Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes. J Clin Invest. 2006;116(12):3171-82.